A Phase 3 interventional study of Cenegermin and Vehicle in Dry Eye Disease, sponsored by Dompé Farmaceutici S.p.A. Completed at 10 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-26.
Sponsored by Dompé Farmaceutici S.p.A · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Dry Eye Syndromes by Dompé Farmaceutici S.p.A — 1 open to participants now, 1 under way, none of them phase 3. Dry Eye Syndromes · Dompé Farmaceutici S.p.A.
Among the 10 studies in Dry Eye Syndromes by Dompé Farmaceutici S.p.A, this one is one of 2 that started in 2022, is one of 2 in phase 3, and was the 6th registered.
1,369 studies on the registry are indexed under Dry Eye Syndromes; 208 are open to participants now.
Browse Dry Eye Syndromes studies →1 of the 10 studies in Dry Eye Syndromes by Dompé Farmaceutici S.p.A is open now, in 1 country. Recruiting first, the newest first:
Dompé Farmaceutici S.p.A · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 2 started in 2022.
This study's enrollment of 85 is above the median of 60 across 1,129 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 104 across the 9 interventional studies, 103 across the 1 observational. Of the 9 that completed or were terminated, 8 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
Dompé Farmaceutici S.p.A is the lead sponsor of 52 studies on the registry; 4 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 18 (100%) have results posted.
1 of the studies in Dry Eye Syndromes by Dompé Farmaceutici S.p.A that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07503886Dompé Farmaceutici S.p.AAn Exploratory Efficacy and Safety Study of DFL24498 Topical Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye Disease | 2026-12-27 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Dry Eye Syndromes by Dompé Farmaceutici S.p.A, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Primary Objectives:
Secondary Objectives:
This was a 4 week phase III, multicenter, double-masked, vehicle-controlled study to evaluate safety and efficacy of cenegermin ophthalmic solution at 20 mcg/mL solution versus vehicle, in patients with severe Sjogren's dry eye disease under treatment with Ciclosporine A (or other drugs of the same class).
During the Screening all procedures for inclusion and exclusion were performed. From the day of screening, the patients stopped any kind of further treatment, except CsA and commercially available preservative-free artificial tears provided by the Sponsor for a period of 8 days and 10 days as maximum. At the end of the washout period, patients still meeting the entry criteria for this study were randomized 1:1 and treated for 4 weeks with either cenegermin ophthalmic solution 20 mcg/mL three times a day (TID) or vehicle TID.
In addition to topical CsA eye drops (both groups continued with topical CsA eye drops, or other topical ophthalmic treatment of the same class), during the 4 weeks of masked treatment, only the administration of investigational medicinal product (IMP) was allowed.
During the follow up period, the patient could administer additional preservative-free artificial tear eye drops, provided by the Sponsor, only if strictly needed, and had to document in the patient's Diary the number of additional drops administered for each eye.
Patients were then followed-up for efficacy and safety endpoints until Week 16 and for safety endpoints until Week 24.
The total duration of the study was 25 weeks including 1 week of screening.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with severe Sjögren's DED characterized by the following clinical features:
Exclusion Criteria:
Females of (those who are not surgically sterilized or for at least 1 year) were excluded from participation in the study if they met any one of the following conditions:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One drop of cenegermin 20 mcg/mL (rhNGF 20 mcg/mL), in the pharmaceutical form of ophthalmic sterile solution, was instilled in both eyes three times daily (TID), every six hours.
Drug: Cenegermin
In this arm one drop of vehicle was instilled in both eyes TID for 28 consecutive days.
Other: Vehicle
Oxervate®, an ophthalmic solution containing cenegermin 20 mcg/mL, which is a recombinant human Nerve Growth Factor (rhNGF); one drop of the test product will be instilled in both eyes three times daily (TID) for 28 consecutive days.
Also known as: Oxervate®
Vehicle was instilled with the same scheme of the test product
Also known as: Placebo
Number of Patients With Schirmer I Test (Without Anesthesia) >10mm/5min in the Eligible Eye at Week 4
The Schirmer test was used in ophthalmic examination to measure tear production for the diagnosis of conditions such as keratoconjunctivitis sicca and dry eye. Without previously instilling anesthetic drops, the Schirmer strip was inserted into the lower conjunctival sac at the junction of the lateral and middle thirds, avoiding touching the cornea, and the length of wetting strips in millimeters was recorded after 5 minutes. After 5 minutes had elapsed, the Schirmer's test strip was removed and the length of the tear absorption on the strip was measured (millimeters/5 minutes). Cutoff values: \<5 mm - pathologic dry eye 5-10 mm - marginal dry eye \>10 and \<30 mm - normal secretion The longer, the wetted length, the healthier the status of the eye. No units other than participants were assigned.
Time frame: At Week 4 (Visit 3)
Change From Baseline in Symptom Questionnaire (SANDE) Global Score at Week 12
SANDE was a short questionnaire to evaluate both dry eye intensity and frequency. It uses a 100 mm horizontal line (Visual Analogue Scale - VAS), for each of the 2 questions, to assess ocular discomfort and/or dryness. Frequency of symptoms ranged from "rarely" (best outcome) to "all of the time" (worst outcome), while the severity of symptoms ranged from "very mild" (best outcome) to "very severe" (worst outcome). Patients had to place a mark on the two given lines based on the extent of their symptoms. The locations of the marks was measured in mm from left to right and recorded as frequency and severity scores, respectively. The SANDE lines for intensity and for severity ranged from 0, being the minimal amount of dry eye symptoms (best outcome) to 100, being the maximal amount of dry eye symptoms (worst outcome). The total SANDE score was calculated by multiplying the frequency score by the severity score and obtaining the square root (0-100; the lower, the better).
Time frame: At Week 12 (Visit 5 - Follow up)
Key Secondary Outcome: Number of Patients With Schirmer I Test (Without Anesthesia) >10mm/5min at Week 8
The Schirmer test was used in ophthalmic examination to measure tear production for the diagnosis of conditions such as keratoconjunctivitis sicca and dry eye. Without previously instilling anesthetic drops, the Schirmer strip was inserted into the lower conjunctival sac at the junction of the lateral and middle thirds, avoiding touching the cornea, and the length of wetting strips in millimeters was recorded after 5 minutes. After 5 minutes had elapsed, the Schirmer test strip was removed and the length of the tear absorption on the strip was measured (millimeters/5 minutes). Cutoff values: \<5 mm - pathologic dry eye 5-10 mm - marginal dry eye \>10 and \<30 mm - normal secretion The longer, the wetted length, the healthier the status of the eye. No units other than participants were assigned.
Time frame: At Week 8 (Visit 4)
Key Secondary Outcome: Change From Baseline in Symptom Assessment in Dry Eye Questionnaire (SANDE) Score for Severity at Week 12
The Symptom Assessment in Dry Eye (SANDE) questionnaire was a short questionnaire to evaluate both dry eye intensity/severity and frequency. This questionnaire used a 100 mm horizontal line (Visual Analogue Scale - VAS) for each of the 2 questions to assess ocular discomfort and/or dryness experienced by the patients. In the SANDE questionnaire, frequency of symptoms ranges from "rarely" to "all of the time" and the severity of symptoms ranged from "very mild" to "very severe". Patients were asked to place a mark on the two given lines based on the extent of their symptoms. The locations of the marks was measured in mm from left to right and recorded as frequency and severity scores, respectively. The SANDE scale ranged from 0, being the minimal amount of dry eye symptoms (best outcome) to 100, being the maximal amount of dry eye symptoms (worst outcome). In this outcome severity score at week 12 was assessed.
Time frame: At Week 12 (Visit 5 - Follow-up)
Key Secondary Outcome: Change From Baseline in Symptoms Assessment in Dry Eye Questionnaire (SANDE) Score for Frequency at Week 12
SANDE was a short questionnaire to evaluate both dry eye intensity and frequency. It uses a 100 mm horizontal line (Visual Analogue Scale, VAS), for each of the 2 questions, to assess ocular discomfort and/or dryness. Frequency of symptoms ranged from "rarely" (best outcome) to "all of the time" (worst outcome), while the severity of symptoms ranged from "very mild" (best outcome) to "very severe" (worst outcome). Patients had to place a mark on the two given lines based on the extent of their symptoms. The locations of the marks was measured in mm from left to right and recorded as frequency and severity scores, respectively. The SANDE lines for intensity and for severity ranged from 0, being the minimal amount of dry eye symptoms (best outcome) to 100, being the maximal amount of dry eye symptoms (worst outcome). The total SANDE score was calculated by multiplying the frequency score by the severity score and obtaining the square root (0-100; the lower, the better).
Time frame: At Week 12 (Visit 5 - Follow-up)
Key Secondary Outcome: Change From Baseline in "Quality of Life, Dry Eye Treatment Satisfaction & Bother and Dry Eye Symptom-Bother" Modules Measured by "Impact of Dry Eye on Everyday Life [IDEEL]" Questionnaire at Week 12 and at Week 4.
IDEEL was a 57-item questionnaire that assessed the impact of dry eye symptoms on everyday life. It consisted of 3 modules: * Dry eye Quality of Life (27 items) composed by 3 dimensions: 1. Impact on Daily Activities 2. Emotional Impact 3. Impact on Work Scores for each dimension of this module ranged from 0 to 100, where higher scores indicated less impact on daily activities, on work and emotions. * Treatment Satisfaction \& Bother (8 items) composed by 2 dimensions: 1. Satisfaction with Treatment Effectiveness 2. Treatment-Related Bother / Inconvenience Scores for each dimension of this module range from 0 to 100, where higher scores indicate greater satisfaction with treatment effectiveness and less treatment-related bother. * Symptom Bother (20 items) composed by 1 dimension: 1. Dry Eye Symptom-Bother Scores for the dimension of this module ranged from 0 to 100, where higher scores indicated a greater symptom bother. No combination of dimensions scores was done.
Time frame: At Week 12 (Visit 5 - Follow-up) and Week 4 (Visit 3)
Key Secondary Outcome: Change From Baseline in Tear Film Break-Up Time (TFBUT) at Week 4, Week 8 and Week 12
Tear film break-up time (TFBUT) was the time taken to appear first dry spot on cornea after a complete blinking. TFBUT measurement was an easy and fast method used to assess the stability of tear film. It was a standard diagnostic procedure in the dry eye clinics. TFBUT was measured by determining the time to tear break-up. The TFBUT was performed after instillation of 5 μL of 2% preservative-free sodium fluorescein solution into the inferior conjunctival sac of each eye. The patient was instructed to blink several times to thoroughly mix the fluorescein with the tear film. A TFBUT greater than 15 seconds was considered normal, while a break time of less than 10 seconds was to be considered pathological. Hence, the shorter the time, the worse the outcome.
Time frame: At week 4 (Visit 3) , Week 8 (Visit 4), and Week 12 (Visit 5 - Follow-up)
Change From Baseline in Schirmer I Test (Without Anaesthesia) at Week 4, Week 8, Week 12, and Week 16
The Schirmer test was used in ophthalmic examination to measure tear production for the diagnosis of conditions such as keratoconjunctivitis sicca and dry eye. Without previously instilling anesthetic drops, the Schirmer strip was inserted into the lower conjunctival sac at the junction of the lateral and middle thirds, avoiding touching the cornea, and the length of wetting strips in millimeters was recorded after 5 minutes. After 5 minutes had elapsed, the Schirmer test strip was removed and the length of the tear absorption on the strip was measured (millimeters/5 minutes). Cutoff values: \<5 mm - pathologic dry eye 5-10 mm - marginal dry eye \>10 and \<30 mm - normal secretion The longer, the wetted length, the healthier the status of the eye.
Time frame: At Week 4 (Visit 3), Week 8 (Visit 4), Week 12 (Visit 5), and Week 16 (Visit 6)
Change From Baseline in Cornea and Conjunctiva Vital Staining With Fluorescein (National Eye Institute [NEI] Scales) at Week 4, Week 8, Week 12 and Week 16
The NEI/Industry Workshop guidelines were used for grading the scale of corneal and conjunctival damage. The cornea was divided into five sectors (central, superior, inferior, nasal and temporal), each of which was scored on a scale of 0-3, with a maximal total corneal staining score of 15. Both nasally and temporally, the conjunctiva was divided into a superior paralimbal area, an inferior paralimbal area, and a peripheral area with a grading scale of 0-3 and with a maximal total score of 9 for the nasal and temporal conjunctiva (overall the total score ranged from 0-18). Briefly, grade 0 reflected normal/healthy situation, whereas grade 3 reflected a severe damage in the considered sector.
Time frame: At Week 4 (Visit 3), Week 8 (Visit 4) , Week 12 (Visit 5) and Week 16 (Visit 6)
Change From Baseline in Tear Film Break-Up Time (TFBUT) at Week 4, Week 8, Week 12 and Week 16
Tear film break-up time (TFBUT) was the time taken to appear first dry spot on cornea after a complete blinking. TFBUT measurement was an easy and fast method used to assess the stability of tear film. It was a standard diagnostic procedure in the dry eye clinics. TFBUT was measured by determining the time to tear break-up. The TFBUT was performed after instillation of 5 μL of 2% preservative-free sodium fluorescein solution into the inferior conjunctival sac of each eye. The patient was instructed to blink several times to thoroughly mix the fluorescein with the tear film. A TFBUT greater than 15 seconds was considered normal, while a break time of less than 10 seconds was to be considered pathological. The shorter the time, the worse the outcome.
Time frame: At Week 4 (Visit 3), Week 8 (Visit 4), Week 12 (Visit 5), and Week 16 (Visit 6)
Change From Baseline in Symptoms Questionnaire (SANDE) Global Scores, and for Severity and Frequency at Week 8, Week 12, and Week 16
SANDE was a short questionnaire to evaluate both dry eye intensity and frequency. It uses a 100 mm horizontal line (Visual Analogue Scale - VAS), for each of the 2 questions, to assess ocular discomfort and/or dryness. Frequency of symptoms ranged from "rarely" (best outcome) to "all of the time" (worst outcome), while the severity of symptoms ranged from "very mild" (best outcome) to "very severe" (worst outcome). Patients had to place a mark on the two given lines based on the extent of their symptoms. The locations of the marks was measured in mm from left to right and recorded as frequency and severity scores, respectively. The SANDE lines for intensity and for severity ranged from 0, being the minimal amount of dry eye symptoms (best outcome) to 100, being the maximal amount of dry eye symptoms (worst outcome). The total SANDE score was calculated by multiplying the frequency score by the severity score and obtaining the square root (0-100; the lower, the better).
Time frame: At Week 8 (Visit 4), Week 12 (Visit 5), and Week 16 (Visit 6)
Number of Patients Experienced a Worsening in Symptom Scores (SANDE Global Scores) and/or NEI Score ≥ 50% at Week 4
Symptoms Scores (SANDE) and/or NEI Score were punctually described in the previous outcome descriptions. For Sande score, the scale ranges from 0 to 100 for both severity and frequency, where 0 was the best condition and 100 marked the worst condition. Hence the higher the score, the worse the outcome. For NEI score, the maximum score (worst outcome) was 15, and the minimum (best outcome) was 0; hence the higher the score, the worse the outcome. Please note that mean is an adjusted mean.
Time frame: At Week 4 (Visit 3)
Change From Baseline in "Quality of Life, Dry Eye Treatment Satisfaction & Bother and Dry Eye Symptom-Bother" Modules Measured by "Impact of Dry Eye on Everyday Life [IDEEL]" Questionnaire at Week 4, Week, 8, Week 12, and Week 16
IDEEL was a 57-item questionnaire that assessed the impact of dry eye symptoms on everyday life. It consisted of 3 modules: * Dry eye Quality of Life (27 items) composed by 3 dimensions: 1. Impact on Daily Activities 2. Emotional Impact 3. Impact on Work Scores for each dimension of this module ranged from 0 to 100, where higher scores indicated less impact on daily activities, on work and emotions. * Treatment Satisfaction \& Bother (8 items) composed by 2 dimensions: 1. Satisfaction with Treatment Effectiveness 2. Treatment-Related Bother / Inconvenience Scores for each dimension of this module range from 0 to 100, where higher scores indicate greater satisfaction with treatment effectiveness and less treatment-related bother. * Symptom Bother (20 items) composed by 1 dimension: 1. Dry Eye Symptom-Bother. Scores for the dimension of this module ranged from 0 to 100, where higher scores indicated greater symptom bother. No combination of dimensions scores was done.
Time frame: At Week 4 (Visit 3), Week 8 (Visit 4), Week 12 (Visit 5), and Week 16 (Visit 6)
Number of Patients With at Least One Treatment-emergent Adverse Event (TEAE) From Screening Day to Week 24
Treatment emergent adverse events (TEAEs) were undesirable events not present prior to medical treatment, or an already present event that worsens either in intensity or frequency following the treatment.
Time frame: From Screening day (Day -8) up to Week 24 (Visit 7 - Follow-up)
Use of Preservative Free Artificial Tears Use (Number of Drops/Day).
Use of Preservative Free Artificial Tears by Study Period is calculated as: total number of drops of the preservative free artificial tears during the X period/ total number of days of the X period \* 100.
Time frame: Treatment period (Day 1 to Week 4), Follow-up period (Week 4 to Week 24), Overall period (Day 1 to Week 24)
Change From Baseline in Schirmer I Test (Without Anaesthesia) at Week 2
The Schirmer test was used in ophthalmic examination to measure tear production for the diagnosis of conditions such as keratoconjunctivitis sicca and dry eye. Without previously instilling anesthetic drops, the Schirmer strip was inserted into the lower conjunctival sac at the junction of the lateral and middle thirds, avoiding touching the cornea, and the length of wetting strips in millimeters was recorded after 5 minutes. After 5 minutes had elapsed, the Schirmer test strip was removed and the length of the tear absorption on the strip was measured (millimeters/5 minutes). Cutoff values: \<5 mm - pathologic dry eye 5-10 mm - marginal dry eye \>10 and \<30 mm - normal secretion The longer, the wetted length, the healthier the status of the eye.
Time frame: At week 2 (Visit 2)
Change From Baseline in Cornea and Conjunctiva Vital Staining With Fluorescein (National Eye Institute [NEI] Scales) at Week 2
The NEI/Industry Workshop guidelines were used for grading the scale of corneal and conjunctival damage. The cornea was divided into five sectors (central, superior, inferior, nasal and temporal), each of which was scored on a scale of 0-3, with a maximal total corneal staining score of 15. Both nasally and temporally, the conjunctiva was divided into a superior paralimbal area, an inferior paralimbal area, and a peripheral area with a grading scale of 0-3 and with a maximal total score of 9 for the nasal and temporal conjunctiva (overall the total score ranged from 0-18). Briefly, grade 0 reflected normal/healthy situation, whereas grade 3 reflected a severe damage in the considered sector.
Time frame: At Week 2 (Visit 2)
Change From Baseline in Tear Film Break-Up Time (TFBUT) at Week 2
Tear film break-up time (TFBUT) was the time taken to appear first dry spot on cornea after a complete blinking. TFBUT measurement was an easy and fast method used to assess the stability of tear film. It was a standard diagnostic procedure in the dry eye clinics. TFBUT was measured by determining the time to tear break-up. The TFBUT was performed after instillation of 5 μL of 2% preservative-free sodium fluorescein solution into the inferior conjunctival sac of each eye. The patient was instructed to blink several times to thoroughly mix the fluorescein with the tear film. A TFBUT greater than 15 seconds was considered normal, while a break time of less than 10 seconds was to be considered pathological.
Time frame: At Week 2 (Visit 2)
Change From Baseline in Symptoms Questionnaire (SANDE) Global Scores, and for Severity and Frequency at Week 2, and Week 4
SANDE was a short questionnaire to evaluate both dry eye intensity and frequency. It uses a 100 mm horizontal line (Visual Analogue Scale - VAS), for each of the 2 questions, to assess ocular discomfort and/or dryness. Frequency of symptoms ranged from "rarely" (best outcome) to "all of the time" (worst outcome), while the severity of symptoms ranged from "very mild" (best outcome) to "very severe" (worst outcome). Patients had to place a mark on the two given lines based on the extent of their symptoms. The locations of the marks was measured in mm from left to right and recorded as frequency and severity scores, respectively. The SANDE lines for intensity and for severity ranged from 0, being the minimal amount of dry eye symptoms (best outcome) to 100, being the maximal amount of dry eye symptoms (worst outcome). The total SANDE score was calculated by multiplying the frequency score by the severity score and obtaining the square root (0-100; the lower, the better).
Time frame: At Week 2 (Visit 2) and Week 4 (Visit 3)
Number of Patients Experienced a Worsening in Symptom Scores (SANDE Global Score) and/or NEI Score ≥ 50% Assessed at Week 2
Symptoms Scores (SANDE) and/or NEI Score were punctually described in the previous outcome descriptions. For Sande score, the scale ranges from 0 to 100 for both severity and frequency, where 0 was the best condition and 100 marked the worst condition. Hence the higher the score, the worse the outcome. For NEI score, the maximum score (worst outcome) was 15, and the minimum (best outcome) was 0; hence the higher the score, the worse the outcome.
Time frame: At Week 2 (Visit 2)
Change From Baseline in Schirmer Test II (With Topical Anaesthesia) at Week 4
Schirmer Test II (with anaesthetic) measured baseline plus reflex secretion. The Schirmer strip was inserted into the lower conjunctival sac at the junction of the lateral and middle thirds, avoiding touching the cornea, and the length of wetting strips in millimeters was recorded after 5 minutes. After 5 minutes had elapsed, the Schirmer test strip was removed and the length of the tear absorption on the strip was measured (millimeters/5 minutes). Cutoff values: \<5 mm - pathologic dry eye 5-10 mm - marginal dry eye \>10 and \<30 mm - normal secretion The longer, the wetted length, the healthier the status of the eye.
Time frame: At Week 4 (Visit 3)
Change From Baseline in Best Corrected Distance Visual Acuity (BCDVA)
Best corrected visual acuity (BCDVA) was determined by careful refraction according to the standard protocol for refraction. Chart 1 was used for testing the VA of the right eye; Chart 2 for the left eye; and Chart R for refraction only. Retroilluminated standard Early Treatment of Diabetic Retinopathy Study (ETDRS) charts were used. They had 5 Sloan letters on each line of equal difficulty, and there was a geometric progression in letter size from line to line. VAS awarded one point for every letter correctly guessed. A distance of 4 meters was required between the subject's eyes and the VA chart. When a subject cannot read at least 20 letters on the chart at 4 meters, the subject was tested at 1 meter. If 20 or more letters were read at 4 meters, the VAS for that eye was recorded as the number of letters correct at 4 meters plus 30. Otherwise, the VAS was the number of letters read correctly at 1 meter plus the number read at 4 meters. The higher the score the better the outcome.
Time frame: At Week 2 (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4), Week 12 (Visit 5), and Week 16 (Visit 6)
Three sites in Italy out of the four opened, and 7 sites in US enrolled patients. A total of 97 adult patients (≥ 18 years) with a diagnosis of severe Sjögren's DED was assessed for eligibility. There were 12 screening failures. The remaining patients (n=85) were randomized 1:1 as follows: 44 to cenegermin and 41 to vehicle. One patient in the vehicle group did not receive study medication and was excluded from the SAF and FAS.
| Milestone | Cenegermin | Vehicle |
|---|---|---|
| Started | 44 | 41 |
| Randomized but not treated | 0 | 1 |
| Safety population (saf) | 44 | 40 |
| Full analysis set population (fas) | 44 | 40 |
| Per protocol set (pp) | 38 | 33 |
| Completed | 41 | 39 |
| Not completed | 3 | 2 |
| Withdrew: Withdrawal by subject | 2 | 2 |
| Withdrew: Can no longer make office visits | 1 | 0 |
The Schirmer test was used in ophthalmic examination to measure tear production for the diagnosis of conditions such as keratoconjunctivitis sicca and dry eye. Without previously instilling anesthetic drops, the Schirmer strip was inserted into the lower conjunctival sac at the junction of the lateral and middle thirds, avoiding touching the cornea, and the length of wetting strips in millimeters was recorded after 5 minutes. After 5 minutes had elapsed, the Schirmer's test strip was removed and the length of the tear absorption on the strip was measured (millimeters/5 minutes). Cutoff values: \<5 mm - pathologic dry eye 5-10 mm - marginal dry eye \>10 and \<30 mm - normal secretion The longer, the wetted length, the healthier the status of the eye. No units other than participants were assigned.
| Participants | Cenegermin - FAS | Vehicle - FAS |
|---|---|---|
| Number of Patients With Schirmer I Test (Without Anesthesia) >10mm/5min in the Eligible Eye at Week 4 | 19 | 4 |
SANDE was a short questionnaire to evaluate both dry eye intensity and frequency. It uses a 100 mm horizontal line (Visual Analogue Scale - VAS), for each of the 2 questions, to assess ocular discomfort and/or dryness. Frequency of symptoms ranged from "rarely" (best outcome) to "all of the time" (worst outcome), while the severity of symptoms ranged from "very mild" (best outcome) to "very severe" (worst outcome). Patients had to place a mark on the two given lines based on the extent of their symptoms. The locations of the marks was measured in mm from left to right and recorded as frequency and severity scores, respectively. The SANDE lines for intensity and for severity ranged from 0, being the minimal amount of dry eye symptoms (best outcome) to 100, being the maximal amount of dry eye symptoms (worst outcome). The total SANDE score was calculated by multiplying the frequency score by the severity score and obtaining the square root (0-100; the lower, the better).
| score on a scale | Cenegermin - FAS | Vehicle - FAS |
|---|---|---|
| Change From Baseline in Symptom Questionnaire (SANDE) Global Score at Week 12 | -12.452 (-19.962 to -4.942) | -13.042 (-20.650 to -5.433) |
The Schirmer test was used in ophthalmic examination to measure tear production for the diagnosis of conditions such as keratoconjunctivitis sicca and dry eye. Without previously instilling anesthetic drops, the Schirmer strip was inserted into the lower conjunctival sac at the junction of the lateral and middle thirds, avoiding touching the cornea, and the length of wetting strips in millimeters was recorded after 5 minutes. After 5 minutes had elapsed, the Schirmer test strip was removed and the length of the tear absorption on the strip was measured (millimeters/5 minutes). Cutoff values: \<5 mm - pathologic dry eye 5-10 mm - marginal dry eye \>10 and \<30 mm - normal secretion The longer, the wetted length, the healthier the status of the eye. No units other than participants were assigned.
| Participants | Cenegermin - FAS | Vehicle - FAS |
|---|---|---|
| Key Secondary Outcome: Number of Patients With Schirmer I Test (Without Anesthesia) >10mm/5min at Week 8 | 11 | 2 |
The Symptom Assessment in Dry Eye (SANDE) questionnaire was a short questionnaire to evaluate both dry eye intensity/severity and frequency. This questionnaire used a 100 mm horizontal line (Visual Analogue Scale - VAS) for each of the 2 questions to assess ocular discomfort and/or dryness experienced by the patients. In the SANDE questionnaire, frequency of symptoms ranges from "rarely" to "all of the time" and the severity of symptoms ranged from "very mild" to "very severe". Patients were asked to place a mark on the two given lines based on the extent of their symptoms. The locations of the marks was measured in mm from left to right and recorded as frequency and severity scores, respectively. The SANDE scale ranged from 0, being the minimal amount of dry eye symptoms (best outcome) to 100, being the maximal amount of dry eye symptoms (worst outcome). In this outcome severity score at week 12 was assessed.
| score on a scale | Cenegermin - FAS | Vehicle - FAS |
|---|---|---|
| Key Secondary Outcome: Change From Baseline in Symptom Assessment in Dry Eye Questionnaire (SANDE) Score for Severity at Week 12 | -11.851 (-19.824 to -3.878) | -12.072 (-20.188 to -3.957) |
SANDE was a short questionnaire to evaluate both dry eye intensity and frequency. It uses a 100 mm horizontal line (Visual Analogue Scale, VAS), for each of the 2 questions, to assess ocular discomfort and/or dryness. Frequency of symptoms ranged from "rarely" (best outcome) to "all of the time" (worst outcome), while the severity of symptoms ranged from "very mild" (best outcome) to "very severe" (worst outcome). Patients had to place a mark on the two given lines based on the extent of their symptoms. The locations of the marks was measured in mm from left to right and recorded as frequency and severity scores, respectively. The SANDE lines for intensity and for severity ranged from 0, being the minimal amount of dry eye symptoms (best outcome) to 100, being the maximal amount of dry eye symptoms (worst outcome). The total SANDE score was calculated by multiplying the frequency score by the severity score and obtaining the square root (0-100; the lower, the better).
| score on a scale | Cenegermin - FAS | Vehicle - FAS |
|---|---|---|
| Key Secondary Outcome: Change From Baseline in Symptoms Assessment in Dry Eye Questionnaire (SANDE) Score for Frequency at Week 12 | -14.606 (-23.007 to -6.204) | -14.770 (-23.258 to -6.281) |
IDEEL was a 57-item questionnaire that assessed the impact of dry eye symptoms on everyday life. It consisted of 3 modules: * Dry eye Quality of Life (27 items) composed by 3 dimensions: 1. Impact on Daily Activities 2. Emotional Impact 3. Impact on Work Scores for each dimension of this module ranged from 0 to 100, where higher scores indicated less impact on daily activities, on work and emotions. * Treatment Satisfaction \& Bother (8 items) composed by 2 dimensions: 1. Satisfaction with Treatment Effectiveness 2. Treatment-Related Bother / Inconvenience Scores for each dimension of this module range from 0 to 100, where higher scores indicate greater satisfaction with treatment effectiveness and less treatment-related bother. * Symptom Bother (20 items) composed by 1 dimension: 1. Dry Eye Symptom-Bother Scores for the dimension of this module ranged from 0 to 100, where higher scores indicated a greater symptom bother. No combination of dimensions scores was done.
| score on a scale | Cenegermin - FAS | Vehicle - FAS |
|---|---|---|
| QoL (Daily activities) - Week 4 | 13.690 (8.034 to 19.346) | 11.312 (5.393 to 17.231) |
| QoL (Daily activities) - Week 12 | 13.769 (7.711 to 19.827) | 6.659 (0.549 to 12.769) |
| QoL (Feelings) - Week 4 | 8.811 (2.356 to 15.266) | 12.977 (6.263 to 19.692) |
| QoL (Feelings) - Week 12 | 11.413 (5.058 to 17.767) | 10.355 (3.923 to 16.787) |
| QoL (Work) - Week 4 | 10.689 (2.183 to 19.195) | 14.596 (5.224 to 23.967) |
| QoL (Work) - Week 12 | 13.225 (5.547 to 20.903) | 13.509 (5.084 to 21.934) |
| Treatment Satisfaction (TS) (Treatment - in general) - Week 4 | 8.708 (2.786 to 14.630) | 8.757 (2.493 to 15.022) |
| TS (Treatment - in general) - Week 12 | 7.281 (1.570 to 12.992) | 5.305 (-0.513 to 11.124) |
| Symptom-Bother - Week 4 | -8.030 (-13.302 to -2.758) | -13.262 (-18.758 to -7.766) |
| Symptom-Bother - Week 12 | -10.814 (-16.220 to -5.407) | -10.657 (-16.102 to -5.212) |
Tear film break-up time (TFBUT) was the time taken to appear first dry spot on cornea after a complete blinking. TFBUT measurement was an easy and fast method used to assess the stability of tear film. It was a standard diagnostic procedure in the dry eye clinics. TFBUT was measured by determining the time to tear break-up. The TFBUT was performed after instillation of 5 μL of 2% preservative-free sodium fluorescein solution into the inferior conjunctival sac of each eye. The patient was instructed to blink several times to thoroughly mix the fluorescein with the tear film. A TFBUT greater than 15 seconds was considered normal, while a break time of less than 10 seconds was to be considered pathological. Hence, the shorter the time, the worse the outcome.
| seconds | Cenegermin - FAS | Vehicle - FAS |
|---|---|---|
| Week 4 | 1.020 (0.253 to 1.787) | 0.225 (-0.586 to 1.036) |
| Week 8 | 0.899 (0.074 to 1.725) | 0.951 (0.088 to 1.813) |
| Week 12 | 0.917 (0.123 to 1.711) | 0.782 (-0.040 to 1.603) |
The Schirmer test was used in ophthalmic examination to measure tear production for the diagnosis of conditions such as keratoconjunctivitis sicca and dry eye. Without previously instilling anesthetic drops, the Schirmer strip was inserted into the lower conjunctival sac at the junction of the lateral and middle thirds, avoiding touching the cornea, and the length of wetting strips in millimeters was recorded after 5 minutes. After 5 minutes had elapsed, the Schirmer test strip was removed and the length of the tear absorption on the strip was measured (millimeters/5 minutes). Cutoff values: \<5 mm - pathologic dry eye 5-10 mm - marginal dry eye \>10 and \<30 mm - normal secretion The longer, the wetted length, the healthier the status of the eye.
| millimeters | Cenegermin - FAS | Vehicle - FAS |
|---|---|---|
| Week 4 | 5.4 ± 5.2 | 1.7 ± 3.2 |
| Week 8 | 4.9 ± 4.5 | 1.5 ± 3.0 |
| Week 12 | 4.1 ± 4.7 | 3.1 ± 6.3 |
| Week 16 | 3.4 ± 4.0 | 2.4 ± 4.9 |
The NEI/Industry Workshop guidelines were used for grading the scale of corneal and conjunctival damage. The cornea was divided into five sectors (central, superior, inferior, nasal and temporal), each of which was scored on a scale of 0-3, with a maximal total corneal staining score of 15. Both nasally and temporally, the conjunctiva was divided into a superior paralimbal area, an inferior paralimbal area, and a peripheral area with a grading scale of 0-3 and with a maximal total score of 9 for the nasal and temporal conjunctiva (overall the total score ranged from 0-18). Briefly, grade 0 reflected normal/healthy situation, whereas grade 3 reflected a severe damage in the considered sector.
| score on a scale | Cenegermin - FAS | Vehicle - FAS |
|---|---|---|
| corneal and conjunctival damage - Week 4 | -3.6 ± 4.6 | -2.4 ± 4.7 |
| corneal and conjunctival damage - Week 8 | -3.1 ± 3.8 | -2.9 ± 3.9 |
| corneal and conjunctival damage - Week 12 | -3.4 ± 4.6 | -3.0 ± 3.8 |
| corneal and conjunctival damage - Week 16 | -2.0 ± 6.9 | -2.3 ± 4.2 |
Tear film break-up time (TFBUT) was the time taken to appear first dry spot on cornea after a complete blinking. TFBUT measurement was an easy and fast method used to assess the stability of tear film. It was a standard diagnostic procedure in the dry eye clinics. TFBUT was measured by determining the time to tear break-up. The TFBUT was performed after instillation of 5 μL of 2% preservative-free sodium fluorescein solution into the inferior conjunctival sac of each eye. The patient was instructed to blink several times to thoroughly mix the fluorescein with the tear film. A TFBUT greater than 15 seconds was considered normal, while a break time of less than 10 seconds was to be considered pathological. The shorter the time, the worse the outcome.
| seconds | Cenegermin - FAS | Vehicle - FAS |
|---|---|---|
| Week 4 | 1.1 ± 2.4 | 0.2 ± 2.2 |
| Week 8 | 0.9 ± 2.5 | 0.9 ± 2.3 |
| Week 12 | 1.0 ± 2.6 | 0.7 ± 1.8 |
| Week 16 | 1.3 ± 2.8 | 1.1 ± 2.5 |
SANDE was a short questionnaire to evaluate both dry eye intensity and frequency. It uses a 100 mm horizontal line (Visual Analogue Scale - VAS), for each of the 2 questions, to assess ocular discomfort and/or dryness. Frequency of symptoms ranged from "rarely" (best outcome) to "all of the time" (worst outcome), while the severity of symptoms ranged from "very mild" (best outcome) to "very severe" (worst outcome). Patients had to place a mark on the two given lines based on the extent of their symptoms. The locations of the marks was measured in mm from left to right and recorded as frequency and severity scores, respectively. The SANDE lines for intensity and for severity ranged from 0, being the minimal amount of dry eye symptoms (best outcome) to 100, being the maximal amount of dry eye symptoms (worst outcome). The total SANDE score was calculated by multiplying the frequency score by the severity score and obtaining the square root (0-100; the lower, the better).
| score on a scale | Cenegermin - FAS | Vehicle - FAS |
|---|---|---|
| Global Score - Week 8 | -12.9 ± 19.0 | -10.3 ± 19.2 |
| Global Score - Week 12 | -9.5 ± 17.0 | -11.3 ± 22.5 |
| Global Score - Week 16 | -9.0 ± 22.3 | -11.1 ± 19.0 |
| Severity - Week 8 | -10.7 ± 19.6 | -9.9 ± 20.9 |
| Severity - Week 12 | -8.6 ± 19.6 | -10.2 ± 25.1 |
| Severity - Week 16 | -7.9 ± 22.9 | -10.2 ± 20.2 |
| Frequency - Week 8 | -16.4 ± 23.2 | -10.9 ± 21.2 |
| Frequency - Week 12 | -10.3 ± 23.6 | -12.3 ± 23.5 |
| Frequency - Week 16 | -10.5 ± 24.2 | -12.2 ± 18.6 |
Symptoms Scores (SANDE) and/or NEI Score were punctually described in the previous outcome descriptions. For Sande score, the scale ranges from 0 to 100 for both severity and frequency, where 0 was the best condition and 100 marked the worst condition. Hence the higher the score, the worse the outcome. For NEI score, the maximum score (worst outcome) was 15, and the minimum (best outcome) was 0; hence the higher the score, the worse the outcome. Please note that mean is an adjusted mean.
| Participants | Cenegermin - FAS | Vehicle - FAS |
|---|---|---|
| Worsening in symptom scores (SANDE global score) | 14 | 5 |
| NEI score >= 50% | 1 | 1 |
| Worsening in symptom scores and/or NEI score >= 50 | 15 | 5 |
IDEEL was a 57-item questionnaire that assessed the impact of dry eye symptoms on everyday life. It consisted of 3 modules: * Dry eye Quality of Life (27 items) composed by 3 dimensions: 1. Impact on Daily Activities 2. Emotional Impact 3. Impact on Work Scores for each dimension of this module ranged from 0 to 100, where higher scores indicated less impact on daily activities, on work and emotions. * Treatment Satisfaction \& Bother (8 items) composed by 2 dimensions: 1. Satisfaction with Treatment Effectiveness 2. Treatment-Related Bother / Inconvenience Scores for each dimension of this module range from 0 to 100, where higher scores indicate greater satisfaction with treatment effectiveness and less treatment-related bother. * Symptom Bother (20 items) composed by 1 dimension: 1. Dry Eye Symptom-Bother. Scores for the dimension of this module ranged from 0 to 100, where higher scores indicated greater symptom bother. No combination of dimensions scores was done.
| score on a scale | Cenegermin - FAS | Vehicle - FAS |
|---|---|---|
| QoL (Impact on Daily Activities) - Week 4 | 10.9 ± 20.7 | 10.3 ± 16.4 |
| QoL (Impact on Daily Activities) - Week 8 | 9.2 ± 20.6 | 7.2 ± 17.0 |
| QoL (Impact on Daily Activities) - Week 12 | 11.9 ± 20.8 | 5.6 ± 19.3 |
| QoL (Impact on Daily Activities) - Week 16 | 10.8 ± 19.6 | 8.1 ± 16.2 |
| QoL (Emotional Impact due to Dry Eye) - Week 4 | 4.3 ± 21.6 | 10.1 ± 17.5 |
| QoL (Emotional Impact due to Dry Eye) - Week 8 | 6.1 ± 20.0 | 8.5 ± 16.0 |
| QoL (Emotional Impact due to Dry Eye) - Week 12 | 7.4 ± 21.8 | 7.4 ± 16.6 |
| QoL (Emotional Impact due to Dry Eye) - Week 16 | 6.7 ± 25.0 | 7.6 ± 16.1 |
| QoL (Impact on Work due to Dry Eye) - Week 4 | 9.8 ± 24.7 | 13.4 ± 16.1 |
| QoL (Impact on Work due to Dry Eye) - Week 8 | 9.5 ± 21.7 | 8.1 ± 14.3 |
| QoL (Impact on Work due to Dry Eye) - Week 12 | 10.4 ± 19.9 | 11.8 ± 20.0 |
| QoL (Impact on Work due to Dry Eye) - Week 16 | 13.6 ± 21.3 | 8.9 ± 15.1 |
| TS (Satisfaction with Effectiveness) - Week 4 | 11.3 ± 30.4 | 10.1 ± 25.1 |
| TS (Satisfaction with Effectiveness) - Week 8 | 12.0 ± 25.5 | 5.2 ± 25.2 |
| TS (Satisfaction with Effectiveness) - Week 12 | 13.1 ± 26.8 | 7.4 ± 25.7 |
| TS (Satisfaction with Effectiveness) - Week 16 | 13.1 ± 29.0 | 7.9 ± 26.1 |
| TS (Treatment Bother/Inconvenience) - Week 4 | 5.5 ± 21.7 | 6.2 ± 12.7 |
| TS (Treatment Bother/Inconvenience) - Week 8 | 3.3 ± 18.9 | 5.0 ± 14.8 |
| TS (Treatment Bother/Inconvenience) - Week 12 | 4.5 ± 19.8 | 4.2 ± 12.4 |
| TS (Treatment Bother/Inconvenience) - Week 16 | 5.4 ± 18.5 | 3.3 ± 11.3 |
| Symptom-Bother - Week 4 | -5.8 ± 18.7 | -11.9 ± 12.5 |
| Symptom-Bother - Week 8 | -7.2 ± 16.4 | -7.9 ± 12.9 |
| Symptom-Bother - Week 12 | -8.6 ± 15.5 | -9.5 ± 17.7 |
| Symptom-Bother - Week 16 | -8.0 ± 17.0 | -9.2 ± 13.9 |
Treatment emergent adverse events (TEAEs) were undesirable events not present prior to medical treatment, or an already present event that worsens either in intensity or frequency following the treatment.
| Participants | Cenegermin - SAF | Vehicle - SAF |
|---|---|---|
| Any TEAE | 27 | 18 |
| Any TEAE - Ophtalmic | 26 | 12 |
| Any TEAE . Non-ophtalmic | 9 | 9 |
| Any severe TEAE | 0 | 1 |
| Any severe TEAE - Ophtalmic | 0 | 1 |
| Any severe TEAE - Non-ophtalmic | 0 | 0 |
| Any serious TEAE | 0 | 0 |
| Any serious TEAE - Ophtalmic | 0 | 0 |
| Any serious TEAE - Non-ophtalmic | 0 | 0 |
| Any non-serious TEAE | 27 | 18 |
| Any ADR | 26 | 12 |
| Any ADR - Ophtalmic | 26 | 10 |
| Any ADR - Non-ophtalmic | 3 | 4 |
| Any Serious ADR | 0 | 0 |
| Any Serious ADR leading to IMP discontinuation | 0 | 1 |
| Any TEAE leading to study discontinuation | 0 | 1 |
| Any TEAE leading to death | 0 | 0 |
Use of Preservative Free Artificial Tears by Study Period is calculated as: total number of drops of the preservative free artificial tears during the X period/ total number of days of the X period \* 100.
| number of drops | Cenegermin - FAS | Vehicle - FAS |
|---|---|---|
| Treatment period | 261.2 ± 220.2 | 215.7 ± 184.7 |
| Follow-up period | 330.0 ± 178.1 | 317.6 ± 168.3 |
| Overall period | 294.7 ± 202.5 | 268.1 ± 182.6 |
The Schirmer test was used in ophthalmic examination to measure tear production for the diagnosis of conditions such as keratoconjunctivitis sicca and dry eye. Without previously instilling anesthetic drops, the Schirmer strip was inserted into the lower conjunctival sac at the junction of the lateral and middle thirds, avoiding touching the cornea, and the length of wetting strips in millimeters was recorded after 5 minutes. After 5 minutes had elapsed, the Schirmer test strip was removed and the length of the tear absorption on the strip was measured (millimeters/5 minutes). Cutoff values: \<5 mm - pathologic dry eye 5-10 mm - marginal dry eye \>10 and \<30 mm - normal secretion The longer, the wetted length, the healthier the status of the eye.
| millimeters | Cenegermin - FAS | Vehicle - FAS |
|---|---|---|
| Change From Baseline in Schirmer I Test (Without Anaesthesia) at Week 2 | 4.4 ± 5.0 | 1.0 ± 2.4 |
The NEI/Industry Workshop guidelines were used for grading the scale of corneal and conjunctival damage. The cornea was divided into five sectors (central, superior, inferior, nasal and temporal), each of which was scored on a scale of 0-3, with a maximal total corneal staining score of 15. Both nasally and temporally, the conjunctiva was divided into a superior paralimbal area, an inferior paralimbal area, and a peripheral area with a grading scale of 0-3 and with a maximal total score of 9 for the nasal and temporal conjunctiva (overall the total score ranged from 0-18). Briefly, grade 0 reflected normal/healthy situation, whereas grade 3 reflected a severe damage in the considered sector.
| score on a scale | Cenegermin - FAS | Vehicle - FAS |
|---|---|---|
| Change From Baseline in Cornea and Conjunctiva Vital Staining With Fluorescein (National Eye Institute [NEI] Scales) at Week 2 | -2.6 ± 4.8 | -2.0 ± 5.2 |
Tear film break-up time (TFBUT) was the time taken to appear first dry spot on cornea after a complete blinking. TFBUT measurement was an easy and fast method used to assess the stability of tear film. It was a standard diagnostic procedure in the dry eye clinics. TFBUT was measured by determining the time to tear break-up. The TFBUT was performed after instillation of 5 μL of 2% preservative-free sodium fluorescein solution into the inferior conjunctival sac of each eye. The patient was instructed to blink several times to thoroughly mix the fluorescein with the tear film. A TFBUT greater than 15 seconds was considered normal, while a break time of less than 10 seconds was to be considered pathological.
| seconds | Cenegermin - FAS | Vehicle - FAS |
|---|---|---|
| Change From Baseline in Tear Film Break-Up Time (TFBUT) at Week 2 | 0.7 ± 2.1 | 0.2 ± 2.0 |
SANDE was a short questionnaire to evaluate both dry eye intensity and frequency. It uses a 100 mm horizontal line (Visual Analogue Scale - VAS), for each of the 2 questions, to assess ocular discomfort and/or dryness. Frequency of symptoms ranged from "rarely" (best outcome) to "all of the time" (worst outcome), while the severity of symptoms ranged from "very mild" (best outcome) to "very severe" (worst outcome). Patients had to place a mark on the two given lines based on the extent of their symptoms. The locations of the marks was measured in mm from left to right and recorded as frequency and severity scores, respectively. The SANDE lines for intensity and for severity ranged from 0, being the minimal amount of dry eye symptoms (best outcome) to 100, being the maximal amount of dry eye symptoms (worst outcome). The total SANDE score was calculated by multiplying the frequency score by the severity score and obtaining the square root (0-100; the lower, the better).
| score on a scale | Cenegermin - FAS | Vehicle - FAS |
|---|---|---|
| Global Score - Change from baseline to Week 2 | -2.1 ± 18.0 | -12.3 ± 13.7 |
| Global Score - Change from baseline to Week 4 | -11.5 ± 17.4 | -15.0 ± 18.0 |
| Severity - Change from baseline to Week 2 | -0.5 ± 20.1 | -12.3 ± 14.9 |
| Severity - Change from baseline to Week 4 | -9.2 ± 19.7 | -13.6 ± 17.2 |
| Frequency - Change from baseline to Week 2 | -3.8 ± 18.9 | -12.0 ± 14.7 |
| Frequency - Change from baseline to Week 4 | -14.5 ± 18.8 | -16.9 ± 22.2 |
Symptoms Scores (SANDE) and/or NEI Score were punctually described in the previous outcome descriptions. For Sande score, the scale ranges from 0 to 100 for both severity and frequency, where 0 was the best condition and 100 marked the worst condition. Hence the higher the score, the worse the outcome. For NEI score, the maximum score (worst outcome) was 15, and the minimum (best outcome) was 0; hence the higher the score, the worse the outcome.
| Participants | Cenegermin - FAS | Vehicle - FAS |
|---|---|---|
| Worsening in symptom scores (SANDE global score) | 17 | 5 |
| NEI score >= 50% | 1 | 0 |
| Worsening in symptom scores and/or NEI score >= 50 | 18 | 5 |
Schirmer Test II (with anaesthetic) measured baseline plus reflex secretion. The Schirmer strip was inserted into the lower conjunctival sac at the junction of the lateral and middle thirds, avoiding touching the cornea, and the length of wetting strips in millimeters was recorded after 5 minutes. After 5 minutes had elapsed, the Schirmer test strip was removed and the length of the tear absorption on the strip was measured (millimeters/5 minutes). Cutoff values: \<5 mm - pathologic dry eye 5-10 mm - marginal dry eye \>10 and \<30 mm - normal secretion The longer, the wetted length, the healthier the status of the eye.
| millimeters | Cenegermin - FAS | Vehicle - FAS |
|---|---|---|
| Change From Baseline in Schirmer Test II (With Topical Anaesthesia) at Week 4 | 4.3 ± 4.2 | 1.4 ± 3.7 |
Best corrected visual acuity (BCDVA) was determined by careful refraction according to the standard protocol for refraction. Chart 1 was used for testing the VA of the right eye; Chart 2 for the left eye; and Chart R for refraction only. Retroilluminated standard Early Treatment of Diabetic Retinopathy Study (ETDRS) charts were used. They had 5 Sloan letters on each line of equal difficulty, and there was a geometric progression in letter size from line to line. VAS awarded one point for every letter correctly guessed. A distance of 4 meters was required between the subject's eyes and the VA chart. When a subject cannot read at least 20 letters on the chart at 4 meters, the subject was tested at 1 meter. If 20 or more letters were read at 4 meters, the VAS for that eye was recorded as the number of letters correct at 4 meters plus 30. Otherwise, the VAS was the number of letters read correctly at 1 meter plus the number read at 4 meters. The higher the score the better the outcome.
| Participants | Cenegermin - FAS | Vehicle - FAS |
|---|---|---|
| CFB to Week 2 - No change | 32 | 29 |
| CFB to Week 2 - 20/63 to 20/40 | 0 | 1 |
| CFB to Week 2 - 20/50 to 20/40 | 0 | 1 |
| CFB to Week 2 - 20/40 to 20/25 | 1 | 1 |
| CFB to Week 2 - 20/32 to 20/20 | 1 | 0 |
| CFB to Week 2 - 20/32 to 20/25 | 1 | 1 |
| CFB to Week 2 - 20/25 to 20/20 | 3 | 2 |
| CFB to Week 2 - 20/20 to 20/16 | 2 | 0 |
| CFB to Week 2 - 20/20 to 20/25 | 1 | 2 |
| CFB to Week 2 - 20/16 to 20/12.5 | 0 | 1 |
| CFB to Week 2 - 20/16 to 20/20 | 1 | 0 |
| CFB to Week 2 - 20/16 to 20/25 | 1 | 0 |
| CFB to Week 2 - 20/16 to 20/32 | 0 | 1 |
| CFB to Week 4 - No change | 31 | 33 |
| CFB to Week 4 - 20/63 to 20/40 | 0 | 1 |
| CFB to Week 4 - 20/40 to 20/25 | 1 | 1 |
| CFB to Week 4 - 20/40 to 20/32 | 1 | 0 |
| CFB to Week 4 - 20/32 to 20/20 | 0 | 1 |
| CFB to Week 4 - 20/32 to 20/25 | 1 | 0 |
| CFB to Week 4 - 20/25 to 20/20 | 3 | 2 |
| CFB to Week 4 - 20/20 to 20/25 | 3 | 0 |
| CFB to Week 4 - 20/20 to 20/32 | 1 | 0 |
| CFB to Week 4 - 20/16 to 20/20 | 2 | 0 |
| CFB to Week 4 - 20/16 to 20/32 | 0 | 1 |
| CFB to Week 8 - No change | 26 | 29 |
| CFB to Week 8 - 20/63 to 20/40 | 0 | 1 |
| CFB to Week 8 - 20/50 to 20/40 | 0 | 1 |
| CFB to Week 8 - 20/40 to 20/20 | 0 | 1 |
| CFB to Week 8 -20/40 to 20/25 | 1 | 0 |
| CFB to Week 8 -20/40 to 20/32 | 1 | 0 |
| CFB to Week 8 - 20/40 to 20/50 | 1 | 0 |
| CFB to Week 8 -20/32 to 20/20 | 1 | 0 |
| CFB to Week 8 -20/32 to 20/25 | 1 | 1 |
| CFB to Week 8 - 20/25 to 20/20 | 2 | 1 |
| CFB to Week 8 - 20/25 to 20/32 | 1 | 0 |
| CFB to Week 8 - 20/20 to 20/16 | 2 | 1 |
| CFB to Week 8 - 20/20 to 20/25 | 2 | 2 |
| CFB to Week 8 - 20/16 to 20/20 | 2 | 0 |
| CFB to Week 8 -20/16 to 20/32 | 0 | 1 |
| CFB to Week 12 - no change | 29 | 30 |
| CFB to Week 12 - 20/63 to 20/80 | 0 | 1 |
| CFB to Week 12 -20/50 to 20/63 | 0 | 1 |
| CFB to Week 12 -20/40 to 20/20 | 0 | 1 |
| CFB to Week 12 - 20/40 to 20/32 | 1 | 0 |
| CFB to Week 12 - 20/32 to 20/20 | 1 | 0 |
| CFB to Week 12 - 20/32 to 20/25 | 1 | 1 |
| CFB to Week 12 - 20/25 to 20/20 | 3 | 1 |
| CFB to Week 12 - 20/25 to 20/32 | 1 | 0 |
| CFB to Week 12 - 20/20 to 20/16 | 0 | 1 |
| CFB to Week 12 -20/20 to 20/25 | 1 | 2 |
| CFB to Week 12 - 20/20 to 20/32 | 1 | 0 |
| CFB to Week 12 -20/16 to 20/20 | 1 | 0 |
| CFB to Week 12 -20/16 to 20/50 | 0 | 1 |
| CFB to Week 12 - 20/12.5 to 20/16 | 1 | 0 |
| CFB to Week 16 - no change | 25 | 27 |
| CFB to Week 16 -20/63 to 20/50 | 0 | 1 |
| CFB to Week 16 -20/50 to 20/40 | 0 | 1 |
| CFB to Week 16 - 20/40 to 20/20 | 0 | 1 |
| CFB to Week 16 -20/40 to 20/25 | 1 | 0 |
| CFB to Week 16 -20/40 to 20/32 | 1 | 0 |
| CFB to Week 16 - 20/40 to 20/50 | 1 | 0 |
| CFB to Week 16 -20/32 to 20/25 | 2 | 2 |
| CFB to Week 16 -20/25 to 20/16 | 0 | 1 |
| CFB to Week 16 -20/25 to 20/20 | 4 | 0 |
| CFB to Week 16 -20/25 to 20/32 | 0 | 2 |
| CFB to Week 16 -20/20 to 20/16 | 3 | 0 |
| CFB to Week 16 -20/20 to 20/25 | 2 | 2 |
| CFB to Week 16 -20/16 to 20/20 | 2 | 1 |
Collected over AEs were collected from the screening visit (Day -8) until last Follow-Up visit (Week 24).. Non-serious events are listed at a 4.5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cenegermin - SAF | 0/44 (0%) | 0/44 (0%) | 27/44 (61.4%) |
| Vehicle - SAF | 0/40 (0%) | 0/40 (0%) | 18/40 (45%) |
| Event | Cenegermin - SAF | Vehicle - SAF |
|---|---|---|
| Eye painEye disorders | 21/44 | 4/40 |
| Eyelid painEye disorders | 7/44 | 0/40 |
| HeadacheNervous system disorders | 3/44 | 4/40 |
| Dry eyeEye disorders | 0/44 | 3/40 |
| Eye dischargeEye disorders | 2/44 | 2/40 |
| Foreign body sensation in eyesEye disorders | 0/44 | 2/40 |
| Vision blurredEye disorders | 1/44 | 2/40 |
| Conjunctival hyperaemiaEye disorders | 2/44 | 1/40 |
| Eye irritationEye disorders | 2/44 | 1/40 |
| PhotophobiaEye disorders | 2/44 | 0/40 |
Full Analysis set (FAS): The FAS population consisted of all randomized patients who received at least one dose of the tnvestigational product. FAS population was analysed according to intention-to-treat (ITT) principle, i.e., by treatment allocation regardless happening of intercurrent events (treatment policy strategy). The FAS population was used for the primary analysis of the study and to present results on efficacy data.
| Age, Categorical(Participants) | Cenegermin - FAS | Vehicle - FAS | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 35 | 27 | 62 |
| >=65 years | 9 | 13 | 22 |
| Age, Continuous(years) | Cenegermin - FAS | Vehicle - FAS | Total |
|---|---|---|---|
| Mean | 55.0 ± 13.93 | 58.1 ± 12.84 | 56.5 ± 13.43 |
| Sex: Female, Male(Participants) | Cenegermin - FAS | Vehicle - FAS | Total |
|---|---|---|---|
| Female | 38 | 35 | 73 |
| Male | 6 | 5 | 11 |
| Ethnicity (NIH/OMB)(Participants) | Cenegermin - FAS | Vehicle - FAS | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 2 | 5 |
| Not Hispanic or Latino | 41 | 38 | 79 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cenegermin - FAS | Vehicle - FAS | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 4 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 4 | 4 | 8 |
| White | 37 | 30 | 67 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 3 | 2 | 5 |
| Region of Enrollment(participants) | Cenegermin - FAS | Vehicle - FAS | Total |
|---|---|---|---|
| United States | 21 | 21 | 42 |
| Italy | 23 | 19 | 42 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2022 to primary completion in May 2023, 15 months.
Results were first posted in Dec 2024, 1 year 6 months after primary completion.
Of 81 industry-sponsored phase 3 interventional studies under Dry Eye Syndromes, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's 15 months is above that.
Counting every sponsor, half of 96 studies reached it within 10 months; a quarter within 7 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cenegermin